What is the efficacy of tigecycline compared with ceftazidime‑avibactam for treating carbapenem‑resistant Enterobacterales intra‑abdominal infections in adult patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ceftazidime-Avibactam is Superior to Tigecycline for Carbapenem-Resistant Enterobacterales Intra-Abdominal Infections

For carbapenem-resistant Enterobacterales (CRE) intra-abdominal infections, ceftazidime-avibactam should be the preferred agent over tigecycline, with the specific regimen determined by the carbapenemase type.

Treatment Algorithm Based on Carbapenemase Type

For KPC-Producing CRE (Most Common in Many Regions)

  • Use ceftazidime-avibactam monotherapy as first-line treatment 1, 2
  • This is the most straightforward scenario with robust guideline support

For NDM-Producing CRE (Metallo-β-lactamase)

  • Preferred: Aztreonam-avibactam (if available) 1
  • Alternative: Ceftazidime-avibactam PLUS aztreonam (when aztreonam-avibactam unavailable) 1, 2
    • This combination is necessary because ceftazidime-avibactam alone is ineffective against metallo-β-lactamases
    • The combination showed 81% 30-day survival versus 56% with polymyxin/tigecycline-based therapy in bloodstream infections 1

For OXA-48-Like Producers

  • Use ceftazidime-avibactam (effective against this carbapenemase type) 1

Why Ceftazidime-Avibactam Over Tigecycline

The evidence strongly favors ceftazidime-avibactam:

Clinical Efficacy Data:

  • Tigecycline FDA trials for complicated intra-abdominal infections showed clinical cure rates of 80.6-91.3% against susceptible organisms 3
  • However, these trials compared tigecycline to imipenem/cilastatin in non-resistant Enterobacterales
  • Critical limitation: Tigecycline has no specific FDA indication or robust trial data for carbapenem-resistant organisms in intra-abdominal infections 3

Comparative Evidence:

  • In critically ill patients with carbapenem-resistant Klebsiella pneumoniae, ceftazidime-avibactam achieved superior clinical cure (51.2% vs 29.0%, P=0.022) and microbiological cure (74.4% vs 33.9%, P<0.001) compared to tigecycline 4
  • Meta-analysis of tigecycline for CRE showed no mortality benefit over other agents, with combination therapy performing better than monotherapy 5
  • Ceftazidime-avibactam demonstrated comparable efficacy to carbapenems in complicated intra-abdominal infections, with 91% clinical cure rates 6

Critical Pitfalls to Avoid

  1. Do NOT use ceftazidime-avibactam alone for NDM-producers - it will fail. You must add aztreonam or use aztreonam-avibactam 1, 2

  2. Obtain rapid carbapenemase testing - treatment selection depends critically on the carbapenemase type. Molecular diagnostics should guide therapy within 24-48 hours 1, 2

  3. Monitor for transaminase elevations when using ceftazidime-avibactam plus aztreonam - occurred in 40% of healthy volunteers at high aztreonam doses, though typically asymptomatic and reversible 1

  4. Avoid tigecycline monotherapy - if tigecycline must be used (due to unavailability of preferred agents), use combination therapy as monotherapy showed inferior outcomes 5

When Tigecycline Might Be Considered

Tigecycline should be relegated to a last-resort option only when:

  • Ceftazidime-avibactam is unavailable
  • The patient has documented susceptibility to tigecycline (MIC ≤2 mg/L)
  • It is used in combination with other active agents (never as monotherapy) 1, 5
  • The patient has hepatic function adequate to tolerate tigecycline

The 2026 IDSA guidelines explicitly recommend ceftazidime-avibactam (with or without aztreonam depending on carbapenemase type) as preferred therapy, with polymyxin- or tigecycline-based regimens showing significantly worse outcomes (56% vs 81% 30-day survival for NDM-producers) 1.

The mortality and morbidity data clearly favor ceftazidime-avibactam-based regimens over tigecycline for carbapenem-resistant Enterobacterales intra-abdominal infections.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.